MGRX shows declining revenue and profitability with deteriorating cash flows, though the company reduced its liabilities and completed a 1-for-15 reverse stock split.
The company's revenue decline of 26% to $456K coupled with reduced gross profit margins indicates operational challenges in this small pharmaceutical company. The reverse stock split and updated share count suggest efforts to maintain Nasdaq listing requirements, while the reduction in liabilities provides some financial flexibility.
MGRX experienced broad financial deterioration with revenue falling 26% to $456K and gross profit declining 34% to $250K, indicating margin compression. Operating cash flow worsened by 20% to negative $5.9M, though the company meaningfully reduced total liabilities by 38% to $891K and cut capital expenditures substantially from $43K to $4K. The overall picture signals a small company struggling with revenue generation and cash burn while taking steps to strengthen its balance sheet position.
Capex reduced 91.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 37.5% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue softened 26% — monitor whether this is cyclical or structural.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →